The role of statins in cancer therapy.

  title={The role of statins in cancer therapy.},
  author={Katja Hindler and Charles S. Cleeland and Edgardo D. Rivera Rivera and Charles D. Collard},
  journal={The oncologist},
  volume={11 3},
Administration of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, to ambulatory patients is associated with a lower incidence of long-term adverse cardiovascular events, including death, myocardial infarction, stroke, atrial fibrillation, and renal dysfunction. However, increasing clinical evidence suggests that statins, independent of their effects on serum cholesterol levels, may also play a potential role in the prevention and treatment of cancer. Specifically… 

Figures and Tables from this paper


These Pleiotropic effects show the predominant use of statins in various clinical events.

Statins: A New Hope for Cancer Therapy

The chemopreventive activity of statins against cancer is suggested to depend on inhibition of cholesterol synthesis together with their antioxidant and anti-inflammatory properties.

The role of statins as therapeutic agents in cancer.

This review summarizes the recent epidemiological evidence and preclinical studies that showed effects of all clinically used statins in vitro and in vivo and considers the results of different observational and retrospective studies focused on association among statins and cancer risk which are still under open discussion.

Role of Statins in Breast Cancer Management: Current Issues and Future Directions

In certain breast cancer cell lines, preclinical studies demonstrated that statins have antiproliferative properties with apoptosis induction properties and decrease in the invasion and metastasis, so incorporation of statin in breast cancer treatment should be encouraged in future randomized control studies.

Novel Uses for Lipid-Lowering Agents

This review will discuss the literature supporting the use of statins to prevent and treat cancer.

A Clinical Review of Statins and Cancer: Helpful or Harmful?

Most of the available evidence suggests a possible beneficial effect of statins on cancer, but further study is needed with better designed trials and/or increased efforts in evaluating cancer as secondary end points in all statin trials until definite conclusions regarding statin effects on cancer risk and occurrence can be made.

Pleiotropic effects of statins: a focus on cancer.

Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer

The pharmacology of the statins is reviewed, providing a comprehensive update of the current knowledge of their effects on tissues, biological processes, and pathological conditions, and the disappointing evidence on the possible future use of statin-based drugs in cancer therapy is dissected.

Anticancer Agents in Combination with Statins

When used along with the other chemo therapeutic agents like prenylation inhibitors, NSAIDS and standard chemotherapeutic agents, they have shown much better results at lower doses with little or no toxicity.



The evolving role of statins in the management of atherosclerosis.

3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitor, Fluvastatin, as a Novel Agent for Prophylaxis of Renal Cancer Metastasis

The results suggest that fluvastatin may effectively inhibit in vitro tumor growth, invasion, angiogenesis, and metastasis of Renca cells, and oral administration of fluVastatin could be a novel, safe, and effective agent for preventing metastases of renal cancer.

The risk of cancer in users of statins.

It is suggested that statins may have a protective effect against cancer and are protective when used longer than 4 years or when more than 1350 defined daily doses are taken.

Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin.

Cerivastatin is at least 10 times more potent than the other statins at inducing apoptosis in AML cell lines and is not cytotoxic to nontransformed human bone marrow progenitors, which strongly support the further testing of cervastatin as a novel anticancer therapeutic alone and in combination with other agents in vivo.

Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study.

The results suggest that cerivastatin inhibits cell signaling pathways involved in the invasiveness and metastatic properties of highly invasive cancers.

The association between 3‐hydroxy‐3‐methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women

Statin use has increased dramatically in the U.S. in the past decade, but statins have been found to be carcinogenic in rodents and one clinical trial found an excess of breast carcinoma cases in the treatment group.

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study.

The results of this study provide some degree of reassurance about the safety of HMG-CoA reductase inhibitors in the face of uncertainty about the long-term impact of these medications on cancer.

Statins Have Biphasic Effects on Angiogenesis

HMG-CoA reductase inhibition has a biphasic dose-dependent effect on angiogenesis that is lipid independent and associated with alterations in endothelial apoptosis and vascular endothelial growth factor signaling.

Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.

  • A. ThibaultD. Samid C. Myers
  • Medicine, Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1996
Treatment with ubiquinone was associated with reversal of lovastatin-induced myopathy, and its prophylactic administration prevented the development of this toxicity in a cohort of 56 patients.

3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Interfere With Angiogenesis by Inhibiting the Geranylgeranylation of RhoA

A new relationship between lipid metabolism and angiogenesis is demonstrated and an antiangiogenic effect of HMG-CoA reductase inhibitors is shown with possible important therapeutic implications.